MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+6.98%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$577M
AUM Growth
+$577M
(-0.78%)
Cap. Flow
-$12.6M
Cap. Flow
% of AUM
-2.19%
Top 10 Holdings %
Top 10 Hldgs %
45.32%
Holding
51
New
8
Increased
10
Reduced
20
Closed
7
Top Buys
| 1 |
Tarsus Pharmaceuticals
TARS
|
$13.8M |
| 2 |
Dyne Therapeutics
DYN
|
$13.8M |
| 3 |
Akebia Therapeutics
AKBA
|
$10.5M |
| 4 |
DBVT
DBV Technologies
DBVT
|
$9.65M |
| 5 |
Edgewise Therapeutics
EWTX
|
$8.07M |
Top Sells
| 1 |
Lantheus
LNTH
|
$22.7M |
| 2 |
United Therapeutics
UTHR
|
$18.2M |
| 3 |
iTeos Therapeutics
ITOS
|
$10.4M |
| 4 |
Twist Bioscience
TWST
|
$10.3M |
| 5 |
Natera
NTRA
|
$9.82M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$445M
| $57.6M | 9.98% | 7,648,268 | – | – |
|
2
Madrigal Pharmaceuticals
MDGL
$9.76B
| $30.4M | 5.27% | 100,415 | – | – |
|
3
Zai Lab
ZLAB
$3.68B
| $26.1M | 4.51% | 745,060 -88,599 | -11% | -$3.1M |
|
4
Guardant Health
GH
$8.41B
| $23M | 3.99% | 442,656 | – | – |
|
5
ARS Pharmaceuticals
SPRY
$1.15B
| $22.7M | 3.94% | 1,303,399 -9,705 | -0.7% | -$169K |
|
|
6
Edgewise Therapeutics
EWTX
$1.51B
| $22.6M | 3.91% | 1,720,741 +615,297 | +56% | +$8.07M |
|
7
Avidity Biosciences
RNA
$5.99B
| $21.6M | 3.74% | 760,022 +45,798 | +6% | +$1.3M |
|
8
PTC Therapeutics
PTCT
$3.92B
| $21.4M | 3.71% | 438,477 -1,500 | -0.3% | -$73.3K |
|
9
Trevi Therapeutics
TRVI
$883M
| $18.6M | 3.23% | 3,406,955 -21,411 | -0.6% | -$117K |
|
10
Oric Pharmaceuticals
ORIC
$994M
| $17.6M | 3.04% | 1,729,378 +329,864 | +24% | +$3.35M |
|
|
11
Natera
NTRA
$23.1B
| $16.7M | 2.9% | 98,924 -58,123 | -37% | -$9.82M |
|
12
Alkermes
ALKS
$4.78B
| $15.7M | 2.72% | 549,262 +211,659 | +63% | +$6.06M |
|
13
MoonLake Immunotherapeutics
MLTX
$3.54B
| $14.8M | 2.56% | 313,571 -2,478 | -0.8% | -$117K |
|
|
MBX
14
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $14.8M | 2.56% | 1,294,416 +161,466 | +14% | +$1.84M |
|
15
Compass Therapeutics
CMPX
$483M
| $14.6M | 2.53% | 5,622,505 -2,820,278 | -33% | -$7.33M |
|
16
Ultragenyx Pharmaceutical
RARE
$2.89B
| $14.4M | 2.49% | 395,700 -2,745 | -0.7% | -$99.8K |
|
17
Janux Therapeutics
JANX
$1.37B
| $14.2M | 2.46% | 614,282 +47,089 | +8% | +$1.09M |
|
|
18
Tarsus Pharmaceuticals
TARS
$2.47B
| $13.8M | 2.4% | +341,496 | New | +$13.8M |
|
|
19
Dyne Therapeutics
DYN
$1.92B
| $13.8M | 2.39% | +1,446,361 | New | +$13.8M |
|
20
Vera Therapeutics
VERA
$1.38B
| $13.3M | 2.3% | 563,075 +147,356 | +35% | +$3.47M |
|
21
Crinetics Pharmaceuticals
CRNX
$2.92B
| $12.3M | 2.14% | 428,975 -202,989 | -32% | -$5.84M |
|
22
Revolution Medicines
RVMD
$7.1B
| $11.6M | 2.01% | 315,722 -1,361 | -0.4% | -$50.1K |
|
|
23
Akebia Therapeutics
AKBA
$833M
| $10.5M | 1.82% | +2,889,125 | New | +$10.5M |
|
24
Olema Pharmaceuticals
OLMA
$375M
| $10.1M | 1.76% | 2,378,762 -551,684 | -19% | -$2.35M |
|
25
Xenon Pharmaceuticals
XENE
$2.98B
| $10.1M | 1.75% | 323,398 +20,000 | +7% | +$626K |
|